These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
453 related articles for article (PubMed ID: 34617967)
1. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021. Woo EJ; Mba-Jonas A; Dimova RB; Alimchandani M; Zinderman CE; Nair N JAMA; 2021 Oct; 326(16):1606-1613. PubMed ID: 34617967 [TBL] [Abstract][Full Text] [Related]
2. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States. Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942 [TBL] [Abstract][Full Text] [Related]
3. Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022. Woo EJ; Gee J; Marquez P; Baggs J; Abara WE; McNeil MM; Dimova RB; Su JR Vaccine; 2023 Jul; 41(30):4422-4430. PubMed ID: 37321898 [TBL] [Abstract][Full Text] [Related]
4. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572 [TBL] [Abstract][Full Text] [Related]
5. Risk of Guillain-Barré Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study. Le Vu S; Bertrand M; Botton J; Jabagi MJ; Drouin J; Semenzato L; Weill A; Dray-Spira R; Zureik M Neurology; 2023 Nov; 101(21):e2094-e2102. PubMed ID: 37788935 [TBL] [Abstract][Full Text] [Related]
6. Post-marketing active surveillance of Guillain Barré Syndrome following COVID-19 vaccination in persons aged ≥12 years in Italy: A multi-database self-controlled case series study. Morciano C; Spila Alegiani S; Menniti Ippolito F; Belleudi V; Trifirò G; Zanoni G; Puccini A; Sapigni E; Mores N; Leoni O; Monaco G; Clagnan E; Zappetti C; Bovo E; Cutillo M; Da Cas R; Massari M PLoS One; 2024; 19(1):e0290879. PubMed ID: 38241309 [TBL] [Abstract][Full Text] [Related]
7. Guillain-Barré Syndrome After Ad26.COV2.S Vaccination. Thant HL; Morgan R; Paese MM; Persaud T; Diaz J; Hurtado L Am J Case Rep; 2022 Feb; 23():e935275. PubMed ID: 35157644 [TBL] [Abstract][Full Text] [Related]
8. No significant increase in Guillain-Barré syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study. Jaffry M; Mostafa F; Mandava K; Rosario S; Jagarlamudi Y; Jaffry K; Kornitzer J; Jedidi K; Khan H; Souayah N Vaccine; 2022 Sep; 40(40):5791-5797. PubMed ID: 36055875 [TBL] [Abstract][Full Text] [Related]
9. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. See I; Su JR; Lale A; Woo EJ; Guh AY; Shimabukuro TT; Streiff MB; Rao AK; Wheeler AP; Beavers SF; Durbin AP; Edwards K; Miller E; Harrington TA; Mba-Jonas A; Nair N; Nguyen DT; Talaat KR; Urrutia VC; Walker SC; Creech CB; Clark TA; DeStefano F; Broder KR JAMA; 2021 Jun; 325(24):2448-2456. PubMed ID: 33929487 [TBL] [Abstract][Full Text] [Related]
10. Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting system. Woo EJ; Dimova RB Vaccine; 2022 Jul; 40(31):4116-4120. PubMed ID: 35667915 [TBL] [Abstract][Full Text] [Related]
11. Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021. See I; Lale A; Marquez P; Streiff MB; Wheeler AP; Tepper NK; Woo EJ; Broder KR; Edwards KM; Gallego R; Geller AI; Jackson KA; Sharma S; Talaat KR; Walter EB; Akpan IJ; Ortel TL; Urrutia VC; Walker SC; Yui JC; Shimabukuro TT; Mba-Jonas A; Su JR; Shay DK Ann Intern Med; 2022 Apr; 175(4):513-522. PubMed ID: 35038274 [TBL] [Abstract][Full Text] [Related]
15. Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome. Meo SA; Shaikh N; Abukhalaf FA; Meo AS Sci Rep; 2024 Aug; 14(1):18767. PubMed ID: 39138276 [TBL] [Abstract][Full Text] [Related]
16. A Rare Variant of Guillain-Barre Syndrome Following Ad26.COV2.S Vaccination. Morehouse ZP; Paulus A; Jasti SA; Bing X Cureus; 2021 Sep; 13(9):e18153. PubMed ID: 34703690 [TBL] [Abstract][Full Text] [Related]
17. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021. Shay DK; Gee J; Su JR; Myers TR; Marquez P; Liu R; Zhang B; Licata C; Clark TA; Shimabukuro TT MMWR Morb Mortal Wkly Rep; 2021 May; 70(18):680-684. PubMed ID: 33956784 [TBL] [Abstract][Full Text] [Related]